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Summary
Background.— Percutaneous closure of large persistent ductus arteriosus using the Amplatzer®
duct occluder is an alternative to surgery. However, this device is not recommended in infants
weighing less than 6 kg.Transcatheter
closure;
Low-body-weight
infants;
Aim.— To evaluate the safety and effectiveness of this procedure in low-body-weight infants.
Methods.— We reviewed retrospectively data for infants weighing less or equal to 6 kg who
underwent percutaneous closure of signiﬁcant persistent ductus arteriosus using the Amplatzer®
duct occluder in France between 1998 and 2007.
Abbreviations: 2D-TTE, two-dimensional transthoracic echocardiography; ADO, Amplatzer® duct occluder; LPA, left pulmonary artery;
PDA, persistent ductus arteriosus; ROC, receiver operating characteristic; SD, standard deviation.
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Amplatzer® duct
occluder
MOTS CLÉS
Canal artériel
persistant ;
Fermeture
percutanée ;
Nourrissons de petit
poids ;
Prothèse Amplatzer®
duct occluder
poids est efﬁcace. Cependant, la fréquence et la sévérité des complications devraient conduire
à choisir la ligature chirurgicale comme traitement de première intention, en attendant les
résultats de la fermeture percutanée avec la nouvelle prothèse ADO II dans cette population.
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ntroduction
urgical closure of PDA has been performed for more than
0 years [1]. PDA transcatheter closure was introduced by
orstmann in 1967 [2]. Since then, many devices designed to
cclude PDA have been developed [3—7]. However, most of
hese devices are associated with major drawbacks, includ-
ng a high incidence of residual shunt and/or embolization,
omplex delivery systems and the need for a large delivery
heath. In cases of large and symptomatic PDA in infants,
ultiple coils can be implanted with low-proﬁle delivery
heaths, but the incidence of residual shunt and emboliza-
ion is high [8—13]. Thus, surgery is currently advised in
nfants with symptomatic PDA [14—16]. More recently, the
DO has been developed for the closure of moderate to
arge PDA [17] and many groups have reported encouraging
esults with this device [16,18—20]. Indeed, many centres
avour transcatheter closure in adults and older children
P
D
6s droits réservés.
ith large PDA because of the lower complication rate,
he cost-effectiveness and the less invasive nature of the
rocedure. However, there are few data on its use in low-
ody-weight infants. Moreover, the use of the ADO device
s not recommended by the manufacturer in children below
kg and 6months of age. The aim of our study was to evalu-
te the safety and effectiveness of the ADO for percutaneous
losure of signiﬁcant PDA in infants weighing less or equal to
kg. To address this issue, data were collected retrospec-
ively from all paediatric catheterization centres in France.
ethodsS. Abadir et al.
Results.— Data for 58 patients (mean weight: 5 kg, range: 3.4—6; mean age: 5.5months, range:
2.1—15.3) were reviewed. Mean angiographic persistent ductus arteriosus minimal diameter was
3.7mm (range: 1—7.5). Implantation of the Amplatzer® duct occluder was successful in 89.7%
of cases. In six (10.3%) patients, the device was not implanted because it would have led to
signiﬁcant aortic obstruction. One procedure-related death occurred in a 4 kg infant (1.7%).
Major and minor complications occurred in 6.9 and 31.0% of patients, respectively. Persistent
ductus arteriosus diameter greater than 3.7mm, type C (tubular shape) and diameter/patient
weight ratio greater than 0.91 were signiﬁcantly associated with an unsuccessful procedure
and/or major complications. During a median 10-month follow-up, no late device embolization
occurred.
Conclusions.— Although percutaneous closure of signiﬁcant persistent ductus arteriosus with
the Amplatzer® duct occluder is effective in low-body-weight infants, the level and severity of
complications indicate surgery as ﬁrst-line treatment, at least until further studies are done to
assess the safety and effectiveness of the new Amplatzer® duct occluder II in low-body-weight
infants.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— La fermeture percutanée de large canaux artériels persistants (CAP) avec la pro-
thèse Amplatzer® Duct Occluder (ADO) est une alternative au traitement chirurgical. Cette
prothèse est déconseillée chez les nourrissons de moins de 6 kg.
Objectif.— Notre objectif a été d’évaluer l’efﬁcacité et la sécurité d’utilisation de cette pro-
thèse dans cette population.
Méthodes.— Les dossiers d’enfants de moins de 6 kg ayant subit une fermeture de CAP par la
prothèse ADO en France entre 1998 et 2007 ont été analysés rétrospectivement.
Résultats.— Cinquante-huit patients (poids moyen : 5 kg [3,4—6] ; âge moyen : 5,5mois
[2,1—15,3]) ont été inclus. Le diamètre minimal angiographique du CAP était de 3,7mm (1—7,5).
La prothèse a été implantée avec succès dans 89,7 % des cas. Chez six patients (10,3 %), la pro-
thèse n’a pas été implantée en raison du risque de subocclusion aortique. Un nourrisson de
4 kg est décédé (1,7 %) secondairement à l’intervention. Le taux de complications majeures
et mineures était de 6,9 et 31,0 %, respectivement. Un CAP de diamètre supérieur ou égal à
3,7mm, de type C (forme tubulaire) et un ratio diamètre du CAP/poids de l’enfant supérieur à
0,91 étaient signiﬁcativement associés à un échec d’intervention et/ou complication majeure.
Aucune embolisation tardive n’est survenue après dix mois de suivi médian.
Conclusions.— La fermeture de CAP signiﬁcatifs avec la prothèse ADO chez les enfants de petitatients
ata were collected for infants weighing less or equal to
kg, who underwent percutaneous closure of signiﬁcant PDA
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pAmplatzer® duct occluder in infants less or equal to 6 kg
with the ADO in France between October 1998 and June
2007. Informed consent was obtained from legal guardians.
The inclusion criteria consisted of clinically symptomatic
PDA in infants weighing less or equal to 6 kg without supra-
systemic pulmonary hypertension. Symptoms of signiﬁcant
PDA included difﬁculty in breathing, repeated respiratory
tract infections, weight stagnation or failure to thrive and
signs of patent heart failure. Indicators of signiﬁcant PDA on
2D-TTE included left atrial and left ventricular volume over-
load and signs of pulmonary hypertension. The former was
classiﬁed as absent, trivial, moderate or severe according
to weight-related dimensions; the latter was graded accord-
ing to duct velocity and ﬂow direction and was classiﬁed as
absent, infrasystemic or isosystemic. PDA minimal diameter
was determined on 2D-TTE before the transcatheter pro-
cedure. Infants who had undergone PDA closure using the
ADO but weighed more than 6 kg and those who had had an
attempted PDA closure using coils were excluded.
Catheterization
PDA percutaneous closure was performed in nine French
tertiary paediatric cardiac centres, as described previously
[17]. Procedures were performed under conscious seda-
tion or general anaesthesia. A lateral view aortogram was
performed before percutaneous closure to determine duct
shape according to Krichenko et al.’s angiographic classi-
ﬁcation [21] and PDA minimal diameter. The PDA minimal
diameter (mm) per patient weight (kg) ratio (PDA/W ratio)
was calculated. PDA length and angle were not measured.
In most cases, the device size selected was 1 to 2mm
greater than the PDAminimal diameter, measured by angiog-
raphy in lateral projection. The lateral view aortogram was
repeated after occlusion to assess residual shunting. Proce-
dural and ﬂuoroscopy times, injected iodine volume (ml/kg)
as well as venous and arterial catheter sizes were recorded.
When measured, a ﬁnal gradient at the aortic or pulmonary
end of the device was considered to be signiﬁcant if greater
than 10mmHg.
Follow-up
All patients underwent clinical and echocardiographic inves-
tigations, before discharge and at 1-month follow-up, to
evaluate the effectiveness of the ADO and to monitor
for possible LPA or aortic stenosis. If needed, a longer
follow-up with additional echocardiograms was scheduled.
Residual shunts were graded on colour Doppler echocar-
diograms as absent, grade I (smoke-like jet) or grade II
(directional jet). LPA and/or aortic obstruction were con-
sidered to be signiﬁcant if Doppler velocity measurements
were greater than 2m/s. Complications related to the pro-
cedure were recorded, classiﬁed as major (death, cardiac
arrest with successful resuscitation, device embolization)
or minor (inguinal haematoma, transient thrombosis of the
femoral artery, blood transfusion, haemolysis, LPA and/or
signiﬁcant aortic stenosis).Statistical analysis
Results are expressed as mean values (SD) and range, or as
median values and range.
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Several risk factors were analysed to establish a possible
igniﬁcant association between these factors and an unsuc-
essful procedure or the occurrence of major complications.
procedure was considered to be unsuccessful when the
evice was not ultimately implanted.
The 2 test was used to determine the existence of an
ssociation between the rate of success in our population
nd qualitative variables. Student’s t-test (or the Wilcoxon
est) was used for numerical variables. ROC curves were
btained for one variable (PDA/W ratio) to ﬁnd the best
ompromise between sensitivity and speciﬁcity. All tests
ere two sided. A p-value < 0.05 was considered to be sig-
iﬁcant. Statistical analysis was performed using SAS® for
indows® software (SAS Institute, 8.02 version; Cary, NC,
SA). ROC curves were obtained using Medcalc® software,
ersion 5.00.
esults
atient characteristics
etween October 1998 and June 2007, 58 infants (72.5%
emale) weighing less or equal to 6 kg underwent attempted
ranscatheter occlusion of a signiﬁcant PDA using the ADO in
rance. The procedure was carried out in one of nine French
atheterization centres. Mean (SD) age was 5.5 (2.7)months
range: 2.1—15.3) and mean (SD) weight was 5 (0.7) kg
range: 3.4—6). All patients were symptomatic: weight stag-
ation or failure to thrive was present in 55 (94.8%) patients,
ifﬁculty in breathing and/or repeated respiratory tract
nfections were present in 24 (41.4%) patients and at least
ne episode of heart failure had occurred in 24 (41.4%)
atients. The PDA was isolated in 29 (50.0%) patients. In the
ther 29 patients, the PDA was associated with another car-
iac malformation (atrial [n = 3] or ventricular [n = 4] septal
efect) or was part of a polymalformation syndrome (n = 22),
he most frequent being Down syndrome (n = 6).
Echocardiographic signs of left atrial and ventricular
verload were present in 43 (74.1%) patients (trivial, n = 8;
oderate, n = 28; severe, n = 7). Pulmonary hypertension
as found in 33 (56.9%) patients (infrasystemic, n = 22;
sosystemic, n = 11). On 2D-TTE, mean (SD) duct diameter
t the narrowest point of the PDA was 4 (1.1) mm (range
—6), as was the median duct diameter.
ersistent ductus arteriosus and procedural
haracteristics
ngiographic mean (SD) duct diameter was 3.7 (1.3)mm at
he narrowest point of the PDA. Median duct size was 3.5mm
range: 1—7.5). Fig. 1 shows the distribution of duct shapes
n our population, according to Krichenko et al.’s classiﬁca-
ion [21]. The different sizes of ADO used in these patients
re shown in Fig. 2.
Delivery of the device was successful in 52 (89.7%)
atients. In six patients, no device was implanted because
f a major risk of aortic subocclusion. One death related to
he procedure occurred in a 4 kg infant, who had a 3.7mm
ype C PDA. An 8× 6 device had been implanted. The posi-
ion was unsatisfactory as the device had toppled into the
ortic lumen. While retrieving the impacted device, car-
536 S. Abadir et al.
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Figure 2. Amplatzer® duct occluder (ADO) device sizes used in
our population of 58 infants. The ﬁrst number (in brackets) cor-
responds to the ADO size, the second to the number of patients
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vigure 1. Distribution of angiographic duct types (A, B, C, D or
) among our population of 58 infants. Values given as number and
ercentage of patients.
iac arrest occurred, leading to severe neurological lesions
nd death 1 month later. The other ﬁve patients under-
ent successful surgical ligation. Table 1 shows the clinical
nd angiographic characteristics of the six unsuccessful
ases.
Major procedural complications occurred in four patients
6.9%): death occurred in one patient (as described earlier),
ardiac arrest with successful resuscitation in two patients
nd device embolization in one patient. Cardiac arrests were
resumably due to aortic obstruction by the device; both
atients recovered without sequelae. The device that had
mbolized in the descending aorta was retrieved and reim-
lanted successfully during the same procedure.
Minor procedural complications occurred in 18 (31.0%)
atients. Nine patients had signiﬁcant aortic and/or LPA
rotrusion of the device assessed during catheterization
r by Doppler TTE measurements after the procedure.
ne patient also had a blood transfusion and another had
c
T
ﬂ
T
Table 1 Unsuccessful procedures.
Patient
number
Age
(months)
Weight
(kg)
Angiographi
PDA diamet
(mm)
8 3.50 4.40 4.50
11 2.10 3.40 3.80
28 3.50 4.00 6.00
40 5.40 4.00 3.70
41 5.70 5.16 4.10
45 9.10 6.00 6.00
Mean 4.88 4.49 4.68
ADO: Amplatzer® duct occluder; PDA: persistent ductus arteriosus; PDA
(mm)/patient weight (kg).mplanted with that device, and the third to the percentage of
atients.
n inguinal haematoma. Five other patients required a
lood transfusion while four had transient femoral pulse
oss.
Technical data were available for 29 (50.0%) patients:
ean (SD) procedural time was 66 (33) minutes, mean (SD)
uoroscopy time was 10.0 (6.6) minutes and mean (SD)
njected iodine volume was 5.7 (2.3)ml/kg. Catheter sizes
ere recorded for 38 (65.5%) patients: a 4 French arterial
atheter was used in 87.0% of recorded cases and a 6 French
enous sheath in 83.0% of recorded cases.
Complete occlusion was demonstrable in the cardiac
atheterization laboratory in 20 out of 52 (38.5%) patients.
he following day, eight patients continued to have residual
ow (grade I in six patients) demonstrated by colour Doppler
TE.
c minimal
er
PDA/W ratio PDA type ADO size
1.02 C —
1.12 C 6/4
1.50 C 10/8
0.93 C 8/6
0.79 C 8/6
1.00 C 10/8
1.06 — —
/W: persistent ductus arteriosus minimal angiographic diameter
Amplatzer® duct occluder in infants less or equal to 6 kg
Follow-up
Seven foreign patients were lost to follow-up (12.1%).
The remaining 45 patients who underwent successful ADO
implantation were followed up for a median of 10months
(range: 0.5—91). Patients showed no recurrent respiratory
infections or signs of heart failure and those who had failed
to thrive had increased their weight. 2D-TTE showed com-
plete regression of signs of volume overload for all but two
patients; one of these patients had a perimembranous ven-
tricular septal defect in addition to the closed PDA. Of the
eight patients demonstrating early residual shunt on TTE,
ﬁve showed complete occlusion at 1 year, two were lost to
follow-up and one asymptomatic patient had a moderate
(grade II) residual shunt at his 8-month visit, but without
echocardiographic signs of volume overload. Of the nine
infants demonstrating signiﬁcant early aortic or LPA steno-
sis, ﬁve were followed up; all showed regression of the
stenosis. All minor aortic obstructions (less than 2 m/s) also
disappeared with child growth.
Risk factors
Risk factors signiﬁcantly associated with the occurrence
of an unsuccessful procedure were identiﬁed, as shown in
Table 2. The ﬁgure of 3.7mm was chosen as a cut-off for
statistical analysis because it corresponded to the mean
angiographic minimal duct diameter in our patients. The
limit for the PDA/W ratio of greater than 0.91 was deter-
mined after constructing an ROC curve. Patient weight alone
(greater or less than 5 kg) was not a risk factor, nor was
isolation status (isolated or not isolated) of the PDA. Down
syndrome did not have any bearing on outcome. There was
no signiﬁcant ‘centre effect’ when analysing results and
complication rates (p > 0.05). For each of the nine centres,
the numbers of patients and major and minor complications
were as follows: centre A (n = 14, one major and six minor
complications); centre B (n = 13, one major and ﬁve minor
complications); centre C (n = 11, four minor complications);
Table 2 Factors predictive of an unsuccessful proce-
dure (univariate analysis).
Factors predictive of an
unsuccessful
procedure
Odds ratio [95%
conﬁdence
interval]
p
PDA type C 22.4 [2.4; 205.7] 0.0062
PDA minimal
angiographic
diameter ≥ 3.7mma
12.4 [1.4; 110.9] 0.0025
PDA/W ratio > 0.91a 27.5 [2.8; 267.6] 0.0015
Patient weight < 5 kg — 0.39 (NS)
Catheterization centre — 0.47 (NS)
Isolated PDA — 0.70 (NS)
NS: not signiﬁcant; PDA: persistent ductus arteriosus; PDA/W:
persistent ductus arteriosus minimal angiographic diameter
(mm)/patient weight (kg).
a These two risk factors were also signiﬁcantly associated with
the occurrence of an unsuccessful procedure and/or major
complications.
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entre D (n = 6, two major and two minor complications);
entre E (n = 4, no complications); centre F (n = 3, one minor
omplication); centres G, H, and I (n = 3, n = 1 and n = 1,
espectively, no complications).
iscussion
o our knowledge, our study of percutaneous closure of
ymptomatic PDA in low-body-weight infants is the largest
eported to date. This study demonstrates that percuta-
eous closure of symptomatic PDA with the ADO in selected
nfants less or equal to 6 kg is feasible and effective, with
success rate of 89.7%. The occlusion rate at 1 year was
00% for those followed up over this period. Major and minor
omplications occurred in 6.9 and 31.0% of cases, respec-
ively. Several risk factors were signiﬁcantly associated with
he occurrence of an unsuccessful procedure and/or major
omplications.
mplatzer® duct occluder occlusion
umerous series have reported the successful use of the
DO in adults or adolescents, with a success rate and occlu-
ion rate at 1 year of more than 99% [18—20]. Fewer and
maller studies of ADO implantation in infants have been
eported [22—25]. We chose to compare our results with
hose found in six other selected studies using Pearson’s 2
est (or Fisher’s test) [19,20,22—25]. All six studies report
DA percutaneous closure using the ADO: three are large
tudies, while the other three have a smaller population size
ut include mainly infants and are therefore similar to ours.
ur success rate was signiﬁcantly lower than those reported
n the six studies mentioned above (p < 0.001), except for
he study of Fischer et al. (p = 0.18) [25]. Overall morbidity
as signiﬁcantly higher in our study (p < 0.001) than in the
ther studies.
Most of these studies agree with the manufacturer’s rec-
mmendation not to use the ADO in infants with a body
eight less than 6 kg. Nevertheless, many centres perform
his procedure, with variable results. The results of the
resent study may give a clearer view of the outcomes of
his procedure in low-body-weight infants, while identifying
recise risk factors.
There are two main concerns about using the ADO in
ow-weight infants: local arterial complications due to the
ize of the sheath and aortic obstruction due to the size
f the isthmus in relation to device size. We encoun-
ered ﬁve local complications (8.6%). All of these patients
ecovered ad integrum during follow-up. This rate is sim-
lar to the rate of 8.3% reported by Fischer el al. [25]
nd lower than the rate of 16.7% reported by Butera et
l. [24] (two of the series reporting ADO implantation in
nfants). Compared with previous devices, ADO implantation
equires smaller-sized introduction sheaths (5—7 French).
hus, fewer vascular access complications occur, as demon-
trated in our series.The six unsuccessful procedures encountered in our series
ere related to the occurrence of aortic subocclusion by the
evice. The size of the aortic isthmus is related to patient
eight. The infants included in our series had lower weights
han those in other reports [22,24,25] and consequently a
5 S. Abadir et al.
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arrower isthmus, thus explaining our higher rate of aortic
ubocclusion and lower success rate. Table 3 summarizes the
ata from these six (adult and paediatric) studies.
Other factors may play a role in the occurrence of suboc-
lusion — for example, the angle between the PDA and the
orta, which is usually an acute angle. Unfortunately, few
entres in France record this information. When the device
s released, there is a rocking motion of the retention disc in
he aorta, which is more problematic when the aortic isth-
us is narrow. It is even more problematic when there is no
mpulla at the aortic end of the PDA, as in PDA types B and
, according to Krichenko’s classiﬁcation. Thus, the prob-
em of the angle between the PDA and the aorta is linked
o the type of PDA. When there is an acute angle and PDA
ype C, the rocking motion of the retention disc leads to
rotrusion of the device directly into the aortic isthmus.
n our series, PDA type C represented 29.3% of all cases
nd was signiﬁcantly associated with an unsuccessful pro-
edure. In previous series reporting the use of ADO in PDA
losure in infants [22,24—26], duct shape was not described
n relation to the occurrence of device protrusion. Other
aediatric series reporting PDA occlusion using coils had a
ower incidence of PDA type C [27,28]. Yet, there may be a
ias: patients selected for coil occlusion usually have a small
DA, which is more likely to have a restricted pulmonary
nd.
In February 2008, AGA Medical Corporation announced
hat it had received European ‘Conformité Européenne’
ark approval for the Amplatzer® duct occluder II (ADO II)
29], which is also a self-expanding nitinol mesh device,
abric-free, shaped into a cylindrical waist with reten-
ion discs on either end. According to the manufacturer,
t can treat (almost) all PDA classiﬁcations but, again,
nly in patients who weigh more than 6 kg and are older
han 6months of age. Further studies will be needed to
ssess its safety and effectiveness in our patient popula-
ion.
Duct length may also be a risk factor for aortic suboc-
lusion — particularly the device length/PDA length ratio.
ndeed, implantation of a ‘long’ device may cause aortic
ubocclusion due to protrusion of the device.
These hypotheses concerning aortic subocclusion suggest
hat PDA is a complex and three-dimensional structure. The
ere measurement of the minimal diameter may not be
ufﬁcient, especially in this infant population, and other
ariables such as PDA type, PDA angle and PDA length should
e evaluated before performing the procedure. Ideally,
here should be a speciﬁc device for each PDA, taking into
ccount all of these variables. Performing a non-invasive
maging technique such as three-dimensional TTE, com-
uted tomography or magnetic resonance imaging, before
atheterization, may be useful for characterizing the aortic
sthmus and detecting those patients more at risk of aortic
ubocclusion.
Our study also demonstrated that patient weight alone
as not statistically associated with an increased risk of fail-
re or complications. However, a PDA/W ratio greater than
.91 was signiﬁcantly associated, emphasizing the fact that
oth factors are important in determining the risk. Ideally,
ur study should also have included patients with signiﬁcant
DA treated by surgical ligation in the same centres dur-
ng the same time period, and those who underwent ADO
Ta
bl
e
3
St
ud
y
Pa
ss
et
al
.
M
as
ur
a
et
Bi
lk
is
et
al
Bu
te
ra
et
a
Fi
sc
he
r
et
Al
-A
ta
et
a
O
ur
st
ud
y
N
R:
no
t
re
p
a
N
o
m
ed
ia
b
M
ea
n
va
lu
c
O
cc
lu
si
on
d
O
cc
lu
si
on
l
H
m
d
h
d
g
g
t
f
t
C
N
A
W
M
a
R
[
[Amplatzer® duct occluder in infants less or equal to 6 kg
implantation but weighed more than 6 kg, to compare out-
comes and complication rates between the three groups.
We have compared our results only with those reported in
the literature for similar populations, as shown in Table 3.
It appears from our results that before using the ADO for
PDA occlusion in symptomatic infants less or equal to 6 kg,
one should consider not only patient weight, but also PDA
type and PDA/W ratio to identify patients at higher risk of
failure or complications. The risk factors identiﬁed in this
preliminary series need to be validated in a prospective
study.
Surgical treatment
For some teams, conventional open surgery remains the
treatment of choice [14]. Mavroudis et al. [30] reported
their 46-year experience of PDA division and ligation, with a
0% mortality rate and 4.4% morbidity rate, which rose to 14%
during the last decade if complications such as blood trans-
fusions were included. This rate would probably be higher
for low-weight infants with large PDA. Moreover, absence
of residual shunt was conﬁrmed during follow-up by aus-
cultation in more than 50% of patients, and thus may have
been underestimated. Concerning video-assisted thoraco-
scopic surgery, this technique is burdened with a high rate
of recurrent laryngeal nerve injuries and chylothorax [31].
No speciﬁc reports have been found for PDA surgery in low-
body-weight infants.
Nevertheless, conventional surgery may have to be con-
sidered as the ﬁrst-line treatment for some infants weighing
less or equal to 6 kg with a symptomatic PDA, especially
those with PDA type C, a PDA diameter greater or equal
to 3.7mm and a PDA/W ratio greater than 0.91.
Study limitations
This is a limited series where only selected patients have
been offered percutaneous closure with the ADO, accord-
ing to their paediatric cardiologist’s opinion, formed with or
without a multidisciplinary discussion. While this approach
certainly introduces a bias, this bias should have favoured
the device, as closure using the ADO had been attempted
only in ‘favourable PDA anatomies’. If all PDA cases had
been included, one can speculate that the results would
have shown even more complications.
Missing data and patients lost to follow-up are related to
the retrospective nature of our study. Because this was not
a controlled study, we did not have a ‘surgical’ group or a
‘percutaneous closure with ADO in infants more than 6 kg’
group to compare our results with and to demonstrate the
inﬂuence of this technique and of patient weight on the suc-
cess and complication rates. Thus, we compared our results
to those reported in the literature. No statistical difference
was found between the nine centres that performed this
procedure, but this may be related to a lack of power of the
statistical analysis due to the small size of our population.Conclusion
Our study demonstrated that percutaneous closure of mod-
erate to large PDA using the ADO in selected infants weighing
[539
ess or equal to 6 kg is effective, with a high success rate.
owever, the complication rate in this population is high,
ainly due to aortic subocclusion related to the use of large
evices. Predictors of failure and/or major complications
ave been identiﬁed: PDA type C, an angiographic PDA
iameter greater or equal to 3.7mm and a PDA/W ratio
reater than 0.91. These should be taken into account to
uide future procedures in this patient population, and even
o indicate surgery as a ﬁrst-line treatment, at least until
urther studies are carried out to assess the safety and effec-
iveness of the new ADO II in low-body-weight infants.
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